Below, we focus on the role of IL-27 and how its anti-tumor potential can be harnessed, as well as how neutralizing the apparent pro-tumor cytokines, IL-30 and IL-35, can further enhance an anti-tumor response in the TME. This evidence concerns the gene IL27 and neoplasm.